Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Price: $0.22 --0%
Financial Fact:
Total other income (expense): 5.14M
Today's EPS Names:
PODC, CLIR, ARDS, More
Financial Fact:
Total other income (expense): 5.14M
Today's EPS Names:
PODC, CLIR, ARDS, More
Join SI Premium – FREE
Orexigen Therapeutics (NASDAQ: OREX) reported Q4 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $14.07 million.
According to IMS Health, 185,944 prescriptions of Contrave (naltrexone HCl and bupropion HCl extended-release tablets) were filled in the fourth quarter of 2015.
For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Full Truck Alliance (YMM) Tops Q2 EPS by 10c; beats on guidance
- Weibo (WB) Tops Q2 EPS by 2c
- Jack Henry (JKHY) Tops Q4 EPS by 13c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
